

Attorney Docket No. US2Goldsborough

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the application of)	
)	Examiner: Shar S. Hashemi
Andrew S. Goldsborough)	
)	Art Unit: 1637
Application No.: 10/031,636)	RECEIVED
<u>.</u>)	JUL 3 1 2003
Filed: April 29, 2002)	<i>/ · · ·</i> *
)	TECH CENTER 1600/2900
For: ISOLATION OF NUCLEIC ACID)	

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service as First Class Mail in an envelope addressed to: Assistant Commissioner for Patents, PO Box 1450, Alexandria, VA 22313-1450 on July 35,2003.

Signed: Augu M. VO

Jacquie M. Vo

INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR §§1.56 AND 1.97(c)

Assistant Commissioner for Patents Washington, DC 20231

Dear Sir:

The references listed in the attached PTO Form 1449, copies of which are attached, may be material to examination of the above-identified patent application. Applicants submit these references in compliance with their duty of disclosure pursuant to 37 CFR §§1.56 and 1.97. The Examiner is requested to make these references of official record in this application.

180.00 OP

07/30/2003 MBLANCO 00000007 10031636

This Information Disclosure Statement is not to be construed as a representation that a search has been made, that additional information material to the examination of this application does not exist, or that these references indeed constitute prior art.

This Information Disclosure Statement is being filed after receipt of the first office action. Accordingly, the required fee of \$180.00 is enclosed. The Commissioner is hereby authorized to charge any deficiencies or overpayments Deposit Account No. 50-2626 (Order No. Goldsborough).

Respectfully submitted,

John M. Lucas Reg. No. 43,373

Transform Pharmaceuticals, Inc. 29 Hartwell Avenue Lexington, MA 02421



Form 1449 (Modified)

Information Disclosure Statement By Applicant Atty Docket No.

US2Goldsborough

Application No.: 10/031,636

Inventor

TE JUL CEIVED Andrew S. Goldsborough

Group 1637

Filing Date

April 29, 2002

(Use Several Sheets if Necessary)

U.S. Patent Documents

Examiner						Sub-	Filing
Initial	No.	Patent No.	Date	Patentee	Class	Class	Date
	Α	5,707,796	1/13/98	Gold et al.			
	В	5,426,180	6/20/95	Kool			
	C	5,872,232	2/16/99	Cook et al.			
	D	5,859,221	1/12/99	Cook et al.			
	Е	5,681,726	10/28/97	Huse et al.			

Foreign Patent or Published Foreign Patent Application

Examiner		Document	Publication	Country or		Sub-	Trans	slation
Initial	No.	No.	Date	Patent Office	Class	class	Yes	No
	F	99/55857	11/4/99	WO				
	G	99/36517	7/22/99	WO				
	Н	99/14346	3/25/99	WO				
	I	92/03568	3/5/92	WO				
	J	98/13526	4/2/98	WO				

Other Documents

Examiner		
Initial	No.	Author, Title, Date, Place (e.g. Journal) of Publication
	K	Heidenrich, Olaf et al., "Chemically Modified RNA: Approaches and Applications", The FASEB Journal, January 1993, Vol. 7
	L	Heidenrich, Olaf et al., "High Activity and Stability of Hammerhead Ribozymes Containing 2'-Modified Pyrimidine Nucleosides and Phosphorothioates", The Journal of Biological Chemistry, Vol. 269, No. 3, January 21, pp. 2131-2138, 1994.
	M	Aurup, Helle et al., "Translation of 2'-Modified mRNA in vitro and in vivo", Nucleic Acids Research, 1994, Vol. 22, No. 23. pp.4963-4968.
	N	Xin, Wei et al., "Treatment of Duck Hepatitis B Virus by Antisense Poly-2'-O-(2,4-Dinitrophenyl)-Oligoribonucleotides", Bioenergetics Laboratory, Natural Sciences Center, State University of NY, Buffalo, July 1998
	0	Iribarren, Adolfo M. et al., "2'-0-Alkyl Oligoribonucleotides as Antisense Probes", Proc. Natl. Acad. Sci, Vol. 87, pp 7747-7751, October 1990.

	P	Inoue, Hideo et al, "Synthesis and Hybridization Studies on Two Complementary Nona(2'-0-methyl) Ribonucleotides", Faculty of Pharmaceutical Sciences, Hokkaido University, Sapporo 060, Japan, June 1987.
	Q	Scherr, Michaela et al., "Synthesis and Properties of Hammerhead Ribozymes Stabilized Against Nucleases by Different 2'-Modifications: Methoxyethoxy-, Fluoro- and Amino Groups", Bioorganic & Medicinal Chemistry Letters, Vol. 7, No. 13, pp. 1791-1796, 1997
Examiner	1.	Date Considered

Examiner: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.